Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome

CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes

(2018) Marcos de Lima et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center

(2018) Stefan O. Ciurea et al.   CANCER

Mechanisms of immune escape after allogeneic hematopoietic cell transplantation

(2018) Robert Zeiser et al.   BLOOD

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

(2018) Uwe Platzbecker et al.   LANCET ONCOLOGY

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

(2017) Bart L. Scott et al.   JOURNAL OF CLINICAL ONCOLOGY

Azacitidine Mitigates Graft-versus-Host Disease via Differential Effects on the Proliferation of T Effectors and Natural Regulatory T Cells In Vivo

(2017) Matthew L. Cooper et al.   JOURNAL OF IMMUNOLOGY

Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial

(2016) Charles Craddock et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML

(2016) F Legrand et al.   BONE MARROW TRANSPLANTATION

Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia

(2016) Mohamad Mohty et al.   HAEMATOLOGICA

Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia

(2016) C. Craddock et al.   HAEMATOLOGICA

Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia

(2016) Mohamad Mohty et al.   HAEMATOLOGICA

Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia

(2016) C. Craddock et al.   HAEMATOLOGICA

Survival of Patients with Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study

(2015) Nelli Bejanyan et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report

(2015) Madan H. Jagasia et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome

(2015) Iskra Pusic et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation

(2015) Z Jedlickova et al.   BONE MARROW TRANSPLANTATION

DNA Methylation Inhibitors in Cancer Therapy: The Immunity Dimension

(2015) Jonathan D. Licht   CELL

DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts

(2015) David Roulois et al.   CELL

Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation

(2015) Andreas D. Ørskov et al.   Oncotarget

Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

(2014) J. M. Middeke et al.   BLOOD

Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R

(2014) M. G. Della Porta et al.   BLOOD

Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT

(2014) B Tessoulin et al.   BONE MARROW TRANSPLANTATION

Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation

(2013) T Schroeder et al.   LEUKEMIA

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation

(2013) T Schroeder et al.   LEUKEMIA

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

(2013) H Yang et al.   LEUKEMIA

Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)

(2012) O. C. Goodyear et al.   BLOOD

Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia

(2011) Djordje Atanackovic et al.   AMERICAN JOURNAL OF HEMATOLOGY

Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation

(2011) M. Fang et al.   BLOOD

Prevention and treatment of acute myeloid leukemia relapse after allogeneic stem cell transplantation

(2011) Betul Oran et al.   CURRENT OPINION IN HEMATOLOGY

Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission

(2011) M. Yanada et al.   HAEMATOLOGICA

Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies

(2011) Mohamed L. Sorror et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

(2011) U Platzbecker et al.   LEUKEMIA

In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia

(2010) J. Choi et al.   BLOOD

Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia

(2010) O. Goodyear et al.   BLOOD

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome

(2010) Marcos de Lima et al.   CANCER

Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting

(2009) L. I. Sanchez-Abarca et al.   BLOOD

Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting

(2009) M Lübbert et al.   BONE MARROW TRANSPLANTATION

Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia

(2009) Elias Jabbour et al.   CANCER

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells

(2009) C Flotho et al.   LEUKEMIA